Dominari Holdings Price to Free Cash Flow Ratio 2010-2024 | DOMH

Dominari Holdings price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Dominari Holdings Price to Free Cash Flow Ratio 2010-2024 | DOMH

Dominari Holdings price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79B
Takeda Pharmaceutical (TAK)$43.3B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.5B
Astellas Pharma (ALPMY)$19.4B
United Therapeutics (UTHR)$16.2B
Summit Therapeutics (SMMT)$13.5B
Shionogi (SGIOY)$12.1B
Neurocrine Biosciences (NBIX)$11.9B
Catalent (CTLT)$10.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.3B
Corcept Therapeutics (CORT)$5.4B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.1B
PTC Therapeutics (PTCT)$3B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Arrowhead Pharmaceuticals (ARWR)$2.3B
NewAmsterdam Pharma (NAMS)$2.3B
Soleno Therapeutics (SLNO)$2.2B
Evotec AG (EVO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Recursion Pharmaceuticals (RXRX)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Ocular Therapeutix (OCUL)$1.4B
Harrow (HROW)$1.4B